BARTOLOMÉ CARRILERO FERNÁNDEZ

Carrilero B, Murcia L, Martínez-Lage L, Segovia M. Side effects of benznidazole treatment in a cohort of patients with Chagas disease in non-endemic country. Rev Esp Quimioter. 2011 Sep;24(3):123-6. PubMed PMID: 21947093.

AÑO: 2011; IF: 0.81

21947093

Thomas MC, Fernández-Villegas A, Carrilero B, Marañón C, Saura D, Noya O, Segovia M, Alarcón de Noya B, Alonso C, López MC. Characterization of an immunodominant antigenic epitope from Trypanosoma cruzi as a biomarker of chronic Chagas' disease pathology. Clin Vaccine Immunol. 2012 Feb;19(2):167-73. doi: 10.1128/CVI.05566-11. Epub 2011 Dec 7. PubMed PMID: 22155766; PubMed Central PMCID: PMC3272920.

AÑO: 2012; IF: 2.598

22155766

Pérez-Molina JA, Rodríguez-Guardado A, Soriano A, Pinazo MJ, Carrilero B, García-Rodríguez M, Salas J, Torrús D, Soler-Ferrer C, Puente S, Haro-González JL, Martín-Rabadán P, Gascon J; Chagas Study Group Of The SEMTSI (Sociedad Española de Medicina Tropical Y Salud Internacional [Spanish Society Of Tropical Medicine And International Health]). Guidelines on the treatment of chronic coinfection by Trypanosoma cruzi and HIV outside endemic areas. HIV Clin Trials. 2011 Nov-Dec;12(6):287-98. doi: 10.1310/hct1206-287. Review. PubMed PMID: 22189148.

AÑO: 2011; IF: 1.638

22189148

Egui A, Thomas MC, Morell M, Marañón C, Carrilero B, Segovia M, Puerta CJ, Pinazo MJ, Rosas F, Gascón J, López MC. Trypanosoma cruzi paraflagellar rod proteins 2 and 3 contain immunodominant CD8(+) T-cell epitopes that are recognized by cytotoxic T cells from Chagas disease patients. Mol Immunol. 2012 Oct;52(3-4):289-98. doi: 10.1016/j.molimm.2012.05.021. Epub 2012 Jun 29. PubMed PMID: 22750229.

AÑO: 2012; IF: 2.645

22750229

Murcia L, Carrilero B, Albajar Viñas P, Segovia M. Nifurtimox chemotherapy: collateral effects in treated Trypanosoma cruzi infected patients. Rev Esp Quimioter. 2012 Mar;25(1):74-5. PubMed PMID: 22488545.

AÑO: 2012; IF: 0.836

22488545